Beyfortus Shows Extended Benefits for Infants Against RSV

A study published in The Lancet Infectious Diseases highlights the benefits of using Beyfortus (nirsevimab) for immunizing infants against respiratory syncytial virus (RSV). The NIRSE-GAL study, conducted in Galicia, Spain, is the first to demonstrate reduced hospitalizations in a second RSV season for infants immunized during the first. Data indicates an 85.9% reduction in RSV-related hospitalizations during the initial season and a 55.3% decrease in the second season.

Statistics from the study show a noteworthy decrease in primary care visits related to respiratory conditions during the first RSV season. Specifically, there was a 30.8% reduction in consultations for acute bronchitis or bronchiolitis. Federico Martinón-Torres of Santiago University Hospital highlights that these results could guide future infant immunization strategies.